Expression of melanoma cell adhesion molecule-1 (MCAM-1) in natalizumab-treated multiple sclerosis

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Expression of melanoma cell adhesion molecule-1 (MCAM-1) in natalizumab-treated multiple sclerosis. / Petersen, E. R.; Ammitzbøll, C.; Søndergaard, H. B.; Oturai, A. B.; Sørensen, P. S.; Nilsson, A. C.; Börnsen, L.; von Essen, M.; Sellebjerg, F.

I: Journal of Neuroimmunology, Bind 337, 577085, 2019.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Petersen, ER, Ammitzbøll, C, Søndergaard, HB, Oturai, AB, Sørensen, PS, Nilsson, AC, Börnsen, L, von Essen, M & Sellebjerg, F 2019, 'Expression of melanoma cell adhesion molecule-1 (MCAM-1) in natalizumab-treated multiple sclerosis', Journal of Neuroimmunology, bind 337, 577085. https://doi.org/10.1016/j.jneuroim.2019.577085

APA

Petersen, E. R., Ammitzbøll, C., Søndergaard, H. B., Oturai, A. B., Sørensen, P. S., Nilsson, A. C., Börnsen, L., von Essen, M., & Sellebjerg, F. (2019). Expression of melanoma cell adhesion molecule-1 (MCAM-1) in natalizumab-treated multiple sclerosis. Journal of Neuroimmunology, 337, [577085]. https://doi.org/10.1016/j.jneuroim.2019.577085

Vancouver

Petersen ER, Ammitzbøll C, Søndergaard HB, Oturai AB, Sørensen PS, Nilsson AC o.a. Expression of melanoma cell adhesion molecule-1 (MCAM-1) in natalizumab-treated multiple sclerosis. Journal of Neuroimmunology. 2019;337. 577085. https://doi.org/10.1016/j.jneuroim.2019.577085

Author

Petersen, E. R. ; Ammitzbøll, C. ; Søndergaard, H. B. ; Oturai, A. B. ; Sørensen, P. S. ; Nilsson, A. C. ; Börnsen, L. ; von Essen, M. ; Sellebjerg, F. / Expression of melanoma cell adhesion molecule-1 (MCAM-1) in natalizumab-treated multiple sclerosis. I: Journal of Neuroimmunology. 2019 ; Bind 337.

Bibtex

@article{3f6c9ddba00b431a8fa14a25d767fcd2,
title = "Expression of melanoma cell adhesion molecule-1 (MCAM-1) in natalizumab-treated multiple sclerosis",
abstract = "The objectives were to study the expression of very late antigen (VLA)-4, melanoma cell adhesion molecule-1 (MCAM-1) and activated leukocyte cell adhesion molecule (ALCAM) on CD4+ T cells during natalizumab treatment and to investigate the association with disease activity. We find that subgroups of autoreactive T cells are retained in peripheral blood, in particular MOG-reactive CD4+ T cells expressing MCAM-1. The expression of MCAM-1 or ALCAM on CD4+ T cells was, however, not clearly associated with disease activity (clinical or MRI) during natalizumab treatment. We confirm upregulation of MCAM-1 on CD4+ T cells during natalizumab treatment while VLA-4 is downregulated.",
keywords = "Adhesion molecules, ALCAM, Blood-brain barrier, MCAM-1, Multiple sclerosis, Natalizumab",
author = "Petersen, {E. R.} and C. Ammitzb{\o}ll and S{\o}ndergaard, {H. B.} and Oturai, {A. B.} and S{\o}rensen, {P. S.} and Nilsson, {A. C.} and L. B{\"o}rnsen and {von Essen}, M. and F. Sellebjerg",
year = "2019",
doi = "10.1016/j.jneuroim.2019.577085",
language = "English",
volume = "337",
journal = "Journal of Neuroimmunology",
issn = "0165-5728",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Expression of melanoma cell adhesion molecule-1 (MCAM-1) in natalizumab-treated multiple sclerosis

AU - Petersen, E. R.

AU - Ammitzbøll, C.

AU - Søndergaard, H. B.

AU - Oturai, A. B.

AU - Sørensen, P. S.

AU - Nilsson, A. C.

AU - Börnsen, L.

AU - von Essen, M.

AU - Sellebjerg, F.

PY - 2019

Y1 - 2019

N2 - The objectives were to study the expression of very late antigen (VLA)-4, melanoma cell adhesion molecule-1 (MCAM-1) and activated leukocyte cell adhesion molecule (ALCAM) on CD4+ T cells during natalizumab treatment and to investigate the association with disease activity. We find that subgroups of autoreactive T cells are retained in peripheral blood, in particular MOG-reactive CD4+ T cells expressing MCAM-1. The expression of MCAM-1 or ALCAM on CD4+ T cells was, however, not clearly associated with disease activity (clinical or MRI) during natalizumab treatment. We confirm upregulation of MCAM-1 on CD4+ T cells during natalizumab treatment while VLA-4 is downregulated.

AB - The objectives were to study the expression of very late antigen (VLA)-4, melanoma cell adhesion molecule-1 (MCAM-1) and activated leukocyte cell adhesion molecule (ALCAM) on CD4+ T cells during natalizumab treatment and to investigate the association with disease activity. We find that subgroups of autoreactive T cells are retained in peripheral blood, in particular MOG-reactive CD4+ T cells expressing MCAM-1. The expression of MCAM-1 or ALCAM on CD4+ T cells was, however, not clearly associated with disease activity (clinical or MRI) during natalizumab treatment. We confirm upregulation of MCAM-1 on CD4+ T cells during natalizumab treatment while VLA-4 is downregulated.

KW - Adhesion molecules

KW - ALCAM

KW - Blood-brain barrier

KW - MCAM-1

KW - Multiple sclerosis

KW - Natalizumab

U2 - 10.1016/j.jneuroim.2019.577085

DO - 10.1016/j.jneuroim.2019.577085

M3 - Journal article

C2 - 31655423

AN - SCOPUS:85073697028

VL - 337

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

SN - 0165-5728

M1 - 577085

ER -

ID: 235593279